EA200800417A1 - Анти-il-23 антитела - Google Patents
Анти-il-23 антителаInfo
- Publication number
- EA200800417A1 EA200800417A1 EA200800417A EA200800417A EA200800417A1 EA 200800417 A1 EA200800417 A1 EA 200800417A1 EA 200800417 A EA200800417 A EA 200800417A EA 200800417 A EA200800417 A EA 200800417A EA 200800417 A1 EA200800417 A1 EA 200800417A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- antigen
- binding portions
- subunit
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Данное изобретение охватывает изолированные антитела или их антигенсвязывающие части, которые специфически связываются с р19 субъединицей IL-23. Данные антитела или их антигенсвязывающие части являются высокоаффинными нейтрализующими антителами, полезными для лечения аутоиммунных заболеваний.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71133605P | 2005-08-25 | 2005-08-25 | |
US77235506P | 2006-02-10 | 2006-02-10 | |
PCT/US2006/032752 WO2007024846A2 (en) | 2005-08-25 | 2006-08-23 | Anit-il-23 antibiodies |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200800417A1 true EA200800417A1 (ru) | 2008-06-30 |
EA013506B1 EA013506B1 (ru) | 2010-06-30 |
Family
ID=37616511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200800417A EA013506B1 (ru) | 2005-08-25 | 2006-08-23 | Антитело к il-23 и его применение |
Country Status (21)
Country | Link |
---|---|
US (1) | US7872102B2 (ru) |
EP (1) | EP1937721B1 (ru) |
JP (1) | JP5022367B2 (ru) |
KR (1) | KR101028200B1 (ru) |
AT (1) | ATE475672T1 (ru) |
AU (1) | AU2006283194B9 (ru) |
BR (1) | BRPI0615018A2 (ru) |
CA (1) | CA2619052A1 (ru) |
CY (1) | CY1110792T1 (ru) |
DE (1) | DE602006015830D1 (ru) |
DK (1) | DK1937721T3 (ru) |
EA (1) | EA013506B1 (ru) |
ES (1) | ES2347690T3 (ru) |
HK (1) | HK1119712A1 (ru) |
IL (1) | IL188312A0 (ru) |
MX (1) | MX2008002179A (ru) |
NO (1) | NO20081465L (ru) |
PL (1) | PL1937721T3 (ru) |
PT (1) | PT1937721E (ru) |
SI (1) | SI1937721T1 (ru) |
WO (1) | WO2007024846A2 (ru) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2710289T3 (es) | 2005-06-30 | 2019-04-24 | Janssen Biotech Inc | Anticuerpos anti-IL-23, composiciones, procedimientos y usos |
SG10201402712QA (en) | 2005-08-31 | 2014-08-28 | Merck Sharp & Dohme | Engineered anti-il-23 antibodies |
RS60616B1 (sr) | 2005-12-29 | 2020-09-30 | Janssen Biotech Inc | Humana anti-il-23 antitela, kompozicije, postupci i upotrebe |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス, インコーポレイテッド | Il−17およびil−23アンタゴニストならびにその使用方法 |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
PL2059534T3 (pl) | 2007-02-23 | 2012-09-28 | Merck Sharp & Dohme | Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej |
CA2678863A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
NZ597915A (en) | 2007-02-28 | 2013-08-30 | Merck Sharp & Dohme | Combination therapy for treatment of immune disorders |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
WO2009023540A1 (en) * | 2007-08-10 | 2009-02-19 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
AR068723A1 (es) * | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
EP2331078B1 (en) | 2008-08-27 | 2012-09-19 | Merck Sharp & Dohme Corp. | Lyophilized formulations of engineered anti-il-23p19 antibodies |
SG2014006860A (en) * | 2008-11-12 | 2014-05-29 | Merck Sharp & Dohme | ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION |
EP2379710A1 (en) | 2008-12-19 | 2011-10-26 | Schering Corporation | Feed supplement for mammalian cell culture and methods of use |
CA2757237A1 (en) | 2009-04-01 | 2010-10-14 | Jane Elizabeth Clarkson | Anti-il-23 immunoglobulins |
US20120264917A1 (en) * | 2009-05-27 | 2012-10-18 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
US20120269765A1 (en) * | 2009-07-24 | 2012-10-25 | Garcia K Christopher | Cytokine compositions and methods of use thereof |
WO2011017294A1 (en) | 2009-08-07 | 2011-02-10 | Schering Corporation | Human anti-rankl antibodies |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
EP2516624B1 (en) | 2009-12-23 | 2020-02-05 | Merck Sharp & Dohme Corp. | Cell line 3m |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
EP3281954A1 (en) | 2010-11-04 | 2018-02-14 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
EP2583979B1 (en) | 2011-10-19 | 2015-12-16 | Effimune | Methods to prepare antibodies directed against p19 subunit of human IL-23 |
EP3326649B1 (en) * | 2012-05-03 | 2022-02-09 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
EP2852615B1 (en) | 2012-05-22 | 2018-12-05 | Bristol-Myers Squibb Company | Il-17a/f il-23 bispecific antibodies and their uses |
ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
JOP20140049B1 (ar) * | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
KR20150128858A (ko) | 2013-03-15 | 2015-11-18 | 암젠 인크 | 항-il-23 항체를 사용한 건선의 치료 방법 |
EP3693007A1 (en) | 2013-03-15 | 2020-08-12 | Amgen, Inc | Methods for treating crohn's disease using an anti-il23 antibody |
US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
WO2016036918A1 (en) | 2014-09-03 | 2016-03-10 | Boehringer Ingelheim International Gmbh | Compound targeting il-23a and tnf-alpha and uses thereof |
AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
CN113559258A (zh) | 2015-02-04 | 2021-10-29 | 勃林格殷格翰国际有限公司 | 治疗炎性疾病的方法 |
JP2018512422A (ja) | 2015-04-14 | 2018-05-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 疾患の処置法 |
RU2018113694A (ru) | 2015-09-17 | 2019-10-17 | Эмджен Инк. | Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23 |
TWI811716B (zh) | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
BR112018012626A2 (pt) | 2015-12-22 | 2018-12-04 | Amgen Inc | ccl20 como um preditor de resposta clínica a antagonistas de il23 |
EP3744733A3 (en) | 2016-04-15 | 2021-02-24 | Boehringer Ingelheim International GmbH | Methods of treating inflammatory diseases |
US20180105588A1 (en) | 2016-10-14 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Methods of treating diseases |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
AR112341A1 (es) | 2017-08-02 | 2019-10-16 | Lilly Co Eli | ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG |
KR20210032441A (ko) | 2018-07-13 | 2021-03-24 | 아스트라제네카 콜라보레이션 벤처스, 엘엘씨 | 브라지쿠맙을 이용한 궤양성 대장염의 치료 |
AU2019383017A1 (en) | 2018-11-20 | 2021-06-03 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
CN113874073A (zh) | 2019-05-23 | 2021-12-31 | 詹森生物科技公司 | 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法 |
CN112807428A (zh) * | 2020-06-12 | 2021-05-18 | 江苏荃信生物医药有限公司 | 包含抗人白介素23单克隆抗体的药物组合物 |
CN114773466B (zh) * | 2020-11-26 | 2023-08-29 | 江苏荃信生物医药股份有限公司 | 一种抗人白介素23及包含其的试剂盒及其检测方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3045480B2 (ja) * | 1996-12-20 | 2000-05-29 | 大同メタル工業株式会社 | ボーリング盤 |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
AU3170199A (en) | 1998-04-14 | 1999-11-08 | Chugai Research Institute For Molecular Medicine, Inc. | Novel cytokine-like protein |
ATE389019T1 (de) * | 1999-09-09 | 2008-03-15 | Schering Corp | Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen |
US20040219150A1 (en) * | 2003-02-06 | 2004-11-04 | Cua Daniel J. | Uses of mammalian cytokine; related reagents |
NZ541898A (en) * | 2003-03-10 | 2008-07-31 | Schering Corp | Uses of IL-23 antagonists for the manufacture of a medicament for the treatment of tumors |
NZ548897A (en) * | 2004-02-17 | 2009-07-31 | Schering Corp | Methods of modulating IL-23 activity; related reagents |
RS60616B1 (sr) * | 2005-12-29 | 2020-09-30 | Janssen Biotech Inc | Humana anti-il-23 antitela, kompozicije, postupci i upotrebe |
CN101662950A (zh) * | 2007-02-22 | 2010-03-03 | 希尔氏宠物营养品公司 | 用于促进骨发育的组合物和方法 |
-
2006
- 2006-08-23 AU AU2006283194A patent/AU2006283194B9/en not_active Ceased
- 2006-08-23 JP JP2008528064A patent/JP5022367B2/ja not_active Expired - Fee Related
- 2006-08-23 BR BRPI0615018-7A patent/BRPI0615018A2/pt not_active IP Right Cessation
- 2006-08-23 EA EA200800417A patent/EA013506B1/ru not_active IP Right Cessation
- 2006-08-23 ES ES06802075T patent/ES2347690T3/es active Active
- 2006-08-23 KR KR1020087004323A patent/KR101028200B1/ko not_active IP Right Cessation
- 2006-08-23 AT AT06802075T patent/ATE475672T1/de active
- 2006-08-23 WO PCT/US2006/032752 patent/WO2007024846A2/en active Application Filing
- 2006-08-23 CA CA002619052A patent/CA2619052A1/en not_active Abandoned
- 2006-08-23 MX MX2008002179A patent/MX2008002179A/es active IP Right Grant
- 2006-08-23 EP EP06802075A patent/EP1937721B1/en not_active Not-in-force
- 2006-08-23 DE DE602006015830T patent/DE602006015830D1/de active Active
- 2006-08-23 PL PL06802075T patent/PL1937721T3/pl unknown
- 2006-08-23 US US11/997,597 patent/US7872102B2/en not_active Expired - Fee Related
- 2006-08-23 PT PT06802075T patent/PT1937721E/pt unknown
- 2006-08-23 SI SI200630791T patent/SI1937721T1/sl unknown
- 2006-08-23 DK DK06802075.9T patent/DK1937721T3/da active
-
2007
- 2007-12-20 IL IL188312A patent/IL188312A0/en unknown
-
2008
- 2008-03-25 NO NO20081465A patent/NO20081465L/no not_active Application Discontinuation
- 2008-10-14 HK HK08111347.9A patent/HK1119712A1/xx not_active IP Right Cessation
-
2010
- 2010-09-23 CY CY20101100855T patent/CY1110792T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7872102B2 (en) | 2011-01-18 |
CY1110792T1 (el) | 2015-06-10 |
SI1937721T1 (sl) | 2010-11-30 |
EA013506B1 (ru) | 2010-06-30 |
DK1937721T3 (da) | 2010-10-18 |
ES2347690T3 (es) | 2010-11-03 |
MX2008002179A (es) | 2008-04-22 |
KR20080031450A (ko) | 2008-04-08 |
IL188312A0 (en) | 2008-04-13 |
JP5022367B2 (ja) | 2012-09-12 |
NO20081465L (no) | 2008-05-15 |
BRPI0615018A2 (pt) | 2011-04-26 |
WO2007024846A3 (en) | 2007-06-07 |
ATE475672T1 (de) | 2010-08-15 |
PL1937721T3 (pl) | 2010-12-31 |
JP2009506041A (ja) | 2009-02-12 |
KR101028200B1 (ko) | 2011-04-11 |
EP1937721A2 (en) | 2008-07-02 |
US20090240036A1 (en) | 2009-09-24 |
AU2006283194A1 (en) | 2007-03-01 |
CA2619052A1 (en) | 2007-03-01 |
DE602006015830D1 (de) | 2010-09-09 |
HK1119712A1 (en) | 2009-03-13 |
PT1937721E (pt) | 2010-09-17 |
EP1937721B1 (en) | 2010-07-28 |
WO2007024846A2 (en) | 2007-03-01 |
AU2006283194B9 (en) | 2011-02-03 |
AU2006283194B2 (en) | 2010-10-21 |
AU2006283194B8 (en) | 2010-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE475672T1 (de) | Anti-il-23-antikörper | |
CY1121208T1 (el) | Σκευασματα αντισωματος ναταλιζουμαμπης | |
LTPA2017040I1 (lt) | Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui | |
TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
EA200870050A1 (ru) | Анти-il-17-антитела | |
EA200900037A1 (ru) | Моноклональные антитела против интерлейкина-6 (il-6) и их применение | |
MX2009006891A (es) | Anticuerpos cd44. | |
NO20084878L (no) | Humanisert C-kit antistoff | |
EA200801362A1 (ru) | Пиримидинил бензотиофеновые соединения | |
UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
EA200800953A1 (ru) | Человеческие моноклональные антитела к cd70 | |
DK1951759T3 (da) | Anti-EGFR-antistoffer | |
EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
TW200740844A (en) | Novel MAdCAM antibodies | |
EA201101593A1 (ru) | КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА | |
TR201901841T4 (tr) | Her antikorlarının sabit dozlaması. | |
DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d | |
EA200700225A1 (ru) | Аналоги тетрапептида | |
EA200970874A1 (ru) | Антитела против склеростина | |
NZ592432A (en) | Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1) | |
EA200701452A1 (ru) | Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4) | |
EA201101241A1 (ru) | Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3 | |
EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
BR112013002831A2 (pt) | anticorpos direcionados contra a il-17 | |
EA201390467A1 (ru) | Композиции антител и способы применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM BY KZ KG MD TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AZ TJ RU |